Senicapoc for worsening lung scarring
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung scarring that is getting worse, diagnosed by a lung specialist.
- You are 18 or older.
- Your breathing test shows lung function is at least 45% of normal, and you have had a clear drop in lung function over the past 6 to 24 months.
- You can walk at least 150 meters in 6 minutes.
- You are not pregnant, are willing to use effective birth control, and have no other major health conditions like severe liver, kidney, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This study tests an inhaled medication for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if the drug is safe and how it works in the body. It might help by targeting the lungs directly with fewer side effects.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.